Document:

ASSET PURCHASE AGREEMENT

 ASSET PURCHASE AGREEMENT, made as of June 5, 2003, by and between Advanced
 Plant Pharmaceuticals, Inc., a Delaware Corporation, with principal offices at
 43 West 33rd Street, New York, New York 10001 (hereinafter referred to as the
 "Seller") and Mazal Plant Pharmaceutical, a Deleware Corporation, with
 principal offices at ________________ (hereinafter referred to as the
 "Purchaser").

                                   WITNESSETH:

 WHEREAS, the Purchaser is engaged in the business of developing, testing,
 manufacturing and selling plant based pharmaceuticals, and is desirous of
 purchasing assets which pertains to the Business of the Purchaser:

 WHEREAS, the Seller has developed a plant based composition designed to treat
 elevated cholesterol ("Lochol") and a plant based composition designed to treat
 leukemia ("Leuknil") and. a plant based composition designed to treat
 Alzheimer's disease (hereinafter referred as "three pharmaceuticals") . The
 seller has also developed a method for producing said plant compositions into a
 drug form

 WHEREAS, the Purchaser is desirous of manufacturing, distributing and selling
 the above THREE PHARMACEUTICALS in any country where it is approved for sale by
 the respective governmental drug and other regulatory agencies;

 NOW, THEREFORE, in consideration of the covenants and agreements hereafter set
 forth, and other valuable consideration, the receipt and sufficiency of which
 hereby are acknowledged, the parties hereto agree as follows:

                                    ARTICLE 1

                           PURCHASE AND SALE OF ASSET

  1.1 Purchase and Sale. Subject to the provisions of this Agreement, the Seller
 shall sell, convey, transfer, assign and deliver to Purchaser, by appropriate
 instruments in form satisfactory to Purchaser, and Purchaser shall purchase and
 accept, for the consideration hereinafter provided, above THREE PHARMACEUTICALS
 and the appurtenant property rights of the Seller described herein,
 specifically including, but without Limitation, the following:

         (a) all rights owned, held or enjoyed by the Seller relating to or
 connected with developing, manufacturing and distributing above THREE
 PHARMACEUTICALS including, but not be limited to, the complete underlying
 dossier and supporting documentation, studies and tests, formulations,
 manufacturing processes, drug delivery methodologies and technical processes;

         (b) all patents. Food and Drug Administration ("FDA") and other United
 States and foreign governmental drug safety and efficacy approvals, approvals
 or licenses of any kind relating to above THREE PHARMACEUTICALS, trademarks
 (either registered or at common), service marks (either registered or at
 common) trade names, service names, labels and copyrights, and all
 registrations and applications worldwide related to above THREE
 PHARMACEUTICALS, and all technical processes, compilations, formulations,
 formulas, recipes and/or other such information related to or connected with
 the development, testing, manufacturing, packaging or repackaging or selling of
 above THREE PHARMACEUTICALS which is owned by the Seller (collectively
 hereinafter referred to as "Intellectual Property Rights");

<PAGE>

(c) copies of all books and records of the Seller relating to studies, trade
secrets, technical information, development, manufacture, distribution and
goodwill, if any, of above THREE PHARMACEUTICALS; (d)the exclusive rights to the
manufacturing process used to make the above THREE PHARMACEUTICALS for the use
of manufacturing any other pharmaceutical compounds or compositions excluding
the rights to manufacture any pharmaceuticals that were previously given to any
other company and excluding the rights to manufacture nutritional products that
are not pharmaceuticals ; and

(e) any and all other property rights of the Seller, of any kind, character and
description, whether tangible or intangible, which are appurtenant to the
ownership of ABOVE THREE PHARMACEUTICALS.

1.2  Purchase Price.

(a) The aggregate purchase price ("Purchase Price") of ABOVE THREE
PHARMACEUTICALS shall be seven million (7,000,000) shares of common stock of
Mazal Plant Pharmaceutical, Inc., $.__ par value ("MPP shares"). The Purchase
Price shall be paid as follows: (1) simultaneously with the execution of this
Agreement, the Purchaser shall issue to Seller seven million (7,000,000) MPP
shares; and (2) the Purchaser agrees to pay to the Seller a royalty of two cents
($0.02) for each and every Months supply of ABOVE THREE PHARMACEUTICALS that the
Purchaser sells for the use of the Sellers processing and manufacturing
technology ("Royalty Payments"). The Purchaser shall pay all Royalty payments to
the Seller on a quarterly basis.

ARTICLE 2

CLOSINGS

<PAGE>

2.1   There has been or shall be delivered, as the case may be, to Purchaser:

(i) Certificates of Title to ABOVE THREE PHARMACEUTICALS

(ii) An Assignment to Purchaser of ownership of any patents, trademarks, service
marks, trade names, service names, labels and copyrights and all registrations
and applications worldwide for ABOVE THREE PHARMACEUTICALS;

(iii) All applicable assignments, material consents and other conveyance
documents, including a Bill of Sale and General Assignment Agreement each in
form substantially similar to that attached hereto as Exhibits A and B with
respect to ABOVE THREE PHARMACEUTICALS;

(iv) Express written consents and approvals to the transfer to Purchaser the
rights to
ABOVE THREE PHARMACEUTICALS as contemplated hereby by all applicable
governmental drug and other regulatory agencies worldwide, and all other
consents or approvals required to effectuate the transaction contemplated
hereby, in form reasonably satisfactory to Purchaser's counsel: and To have and
to hold the same unto Assignee and its assigns forever.

The Asset Purchase Agreement and all of the terms, conditions, representations,
warranties and covenants therein and the schedules and exhibits thereto, are
incorporated into this General Assignment by reference as if same were set forth
herein.

Any provision of this assignment which may be unenforceable or invalid under any
law shall be ineffective to the extent of such unenforceability or invalidity
without affecting the enforceability or validity of any other provision hereof.

IN WITNESS WHEREOF, Seller has caused these presents to be signed in his name on
this 16th day of November, 2004

Advanced Plant Pharmaceuticals, Inc.             Mazal Plant Pharmaceuticals

David Lieberman                                  Mechael Kanovsky
President                                        PresidentTERMINATION AGREEMENT
                       (Six Harrison Street--Fifth Floor)

      This Termination Agreement (this "AGREEMENT"), dated as of May 12, 2005,
is entered into by and among James Thomas Realty, a New York Limited Liability
Company ("LANDLORD"), RMTS, LLC a New York Limited Liability Company ("TENANT")
and Franklin Credit Management Corporation, a Delaware Corporation ("FCMC").

                                    RECITALS

      WHEREAS, LANDLORD, as landlord, and TENANT, as tenant, executed that
certain lease agreement identified on the attached Exhibit A, as amended (the
"LEASE") for premises consisting of the Fifth Floor of the building located at
Number Six Harrison Street, New York, New York (the "FIFTH FLOOR PREMISES").

      WHEREAS, TENANT, as sub-lessor and FCMC as sub-tenant, executed that
certain sublease agreement identified on the attached Exhibit A, as amended (the
"SUBLEASE") for premises consisting of a portion of the Fifth Floor of the
building located at Number Six Harrison Street, New York, New York.

      WHEREAS, LANDLORD, TENANT and FCMC desire to terminate the SUBLEASE prior
to the end of the term of such SUBLEASE.

                                    AGREEMENT

      NOW, THEREFORE, in order to settle and dispose of, fully and completely,
any and all claims, demands and cause or causes of action now existing or
hereafter arising out of, in connection with, or incidental to the termination
of the SUBLEASE or the FIFTH FLOOR PREMISES, and in consideration for the mutual
promises contained herein and for other good and valuable consideration, the
receipt and sufficiency of which are mutually acknowledged, LANDLORD, TENANT and
FCMC agree, effective as of the date hereof, as follows:

      1. Recitals. The foregoing recitals are hereby incorporated herein by
reference and acknowledged as true and correct by the parties hereto.

      2. Termination. Provided that FCMC has complied with its obligations
contained in Section 3 below and the SUBLEASE, effective as of the TERMINATION
DATE (hereinafter defined), the SUBLEASE shall terminate. Except to the extent
inconsistent with the terms hereof, FCMC shall observe and perform each of the
covenants and provisions of the SUBLEASE to be performed by FCMC, including
without limited the payment of rent and additional rent accruing prior to the
TERMINATION DATE.
<PAGE>

      3. Termination Payment. In consideration for the termination of the
SUBLEASE, FCMC shall pay to LANDLORD the amount of $125,000.00 (the "TERMINATION
PAYMENT") payable as follows:

      a) The sum of $10,000.00 shall be paid to LANDLORD within ten (10) days of
execution of this Agreement.

      b) The balance of the TERMINATION PAYMENT shall be paid to LANDLORD on the
TERMINATION DATE.

      4. Vacation of Premises.

      a) Scheduled Surrender Date/Termination Date. Subject to extensions of the
SCHEDULED SURRENDER DATE as set forth in this Section, FCMC shall fully vacate
the FIFTH FLOOR PREMISES on or before August 31, 2005, (such date, as it may be
extended is hereinafter referred to as the "SCHEDULED SURRENDER DATE"; the date
on which FCMC actually vacates the FIFTH FLOOR PREMISES is hereinafter referred
to as the "TERMINATION DATE").

      b) Extension of Termination Date. FCMC may extend the SCHEDULED SURRENDER
DATE for all or any portion of the FIFTH FLOOR PREMISES in one month increments
up to and including November 30, 2005. FCMC shall give TENANT LANDLORD not less
than 30 days prior written notice of any extension of the SCHEDULED SURRENDER
DATE. The rent during the extension period shall be the rent as provided for
under the Sublease. In the event that only a portion of the FIFTH FLOOR PREMISES
is subject to the extension period, the rent shall be pro-rated accordingly.

      c) Termination. Notwithstanding any contrary term herein, the TERMINATION
DATE shall occur not later than November 30, 2005 regardless of whether or not
FCMC vacates the FIFTH FLOOR PREMISES. FCMC shall have no further rights with
respect to the use of the FIFTH FLOOR PREMISES from and after the TERMINATION
DATE.

      d) Condition on Surrender. FCMC shall surrender the FIFTH FLOOR PREMISES
(i) free of all occupants; (ii) in broom clean condition; and (iii) free of all
movable personality and equipment; and (iv) otherwise in its current "AS IS
condition."

      5. Holdover.

      a) In the event FCMC fails to comply with the terms of this Agreement,
LANDLORD shall have the right to retain any and all payments made by FCMC
pursuant to this Agreement and also shall have any and all other rights and
remedies available to LANDLORD under the SUBLEASE to recover the FIFTH FLOOR
PREMISES, at law and in equity, except to the extent inconsistent with the terms
of this Agreement.

                                       2
<PAGE>

      b) FCMC and anyone claiming under FCMC remaining in possession of the
FIFTH FLOOR PREMISES or any part thereof after the TERMINATION DATE shall be
deemed a tenant-at-sufferance only, at the daily rate of 150% of the rent and
additional rent due under the respective SUBLEASE immediately prior to the
Termination Date (the "FINAL RENT RATE") during the first month, 200% of the
Final Rent Rate during the second month and 250% of the Final Rent Rate
thereafter; provided that, notwithstanding any of the foregoing to the contrary,
but subject to the following sentence, FCMC shall remain liable for all damages,
including without limited all direct damages, incurred by LANDLORD as a result
of such holdover. Notwithstanding the foregoing, FCMC shall not be liable for
consequential damages incurred by LANDLORD based upon any holdover by FCMC after
the SCHEDULED SURRENDER DATE unless such holdover continues for ninety (90) or
more says after the SCHEDULED SURRENDER DATE. Nothing in this Section shall be
construed to permit such holding over.

      6. Releases.

      a) Except as to such rights or claims as may be created or otherwise
preserved by this Agreement, LANDLORD and FCMC each hereby releases, remises and
forever discharges the other and its respective officers, directors, employees,
agents, parents, subsidiaries and affiliates from all debts, demands, actions,
causes of action, suits, accounts, covenants, controversies, agreements,
promises, judgments, demands, contracts, agreements, damages, claims and
liabilities whatsoever, in law or equity, in arbitration or otherwise, whether
known or unknown, suspected or unsuspected, related to, arising out of,
connected with or incidental to the SUBLEASE or the FIFTH FLOOR PREMISES.
Nothing contained in this Section shall prevent LANDLORD or FCMC from enforcing
the terms of this Agreement.

      b) Except as to such rights or claims as may be created or otherwise
preserved by this Agreement, TENANT and FCMC each hereby releases, remises and
forever discharges the other and its respective officers, directors, employees,
agents, parents, subsidiaries and affiliates from all debts, demands, actions,
causes of action, suits, accounts, covenants, controversies, agreements,
promises, judgments, demands, contracts, agreements, damages, claims and
liabilities whatsoever, in law or equity, in arbitration or otherwise, whether
known or unknown, suspected or unsuspected, related to, arising out of,
connected with or incidental to the SUBLEASE or the FIFTH FLOOR PREMISES.
Nothing contained in this Section shall prevent TENANT or FCMC from enforcing
the terms of this Agreement.

      7. Notices. Any notice, request or demand ("NOTICE") permitted or required
to be given by the terms and provisions of this Agreement, or by any law or
governmental regulation, either by LANDLORD, TENANT or FCMC, shall be in writing
and delivered by hand (with evidence of receipt), addressed as follows:

                                       3
<PAGE>

      a) To FCMC at No. 6 Harrison Street, Sixth Floor, New York, New York
10016, Attention General Counsel.

      b) To LANDLORD at No. 6 Harrison Street, Fifth Floor, New York, New York
10016, Attention Thomas Axon.

      c) To TENANT at No. 6 Harrison Street, Fifth Floor, New York, New York
10016, Attention David P. Kalm.

      Any party hereto may designate a different address for Notices to such
party by serving Notice of such change in accordance with this section.

      8. Miscellaneous.

      a) This Agreement shall be deemed to have been executed and delivered
within the State of New York, and the rights and obligations of LANDLORD, TENANT
and FCMC hereunder shall be construed and enforced in accordance with, and
governed by, the laws of the State of New York s without regard to the laws
governing conflicts of laws.

      b) If any term of this Agreement or the application thereof to any person
or circumstances shall be invalid and unenforceable, the remaining provisions of
this Agreement, the application or such term to persons or circumstances other
than those as to which it is invalid or unenforceable, shall not be affected.

      c) This Agreement is binding upon and shall inure to the benefit of
LANDLORD, TENANT and FCMC, their respective agents, employees, representatives,
officers, directors, divisions, subsidiaries, affiliates, assigns, heirs,
successors-in-interest and shareholders.

      d) Each party has cooperated in the drafting and preparation of this
Agreement and, therefore, in any construction to be made of this Agreement, the
same shall not be construed against any party hereto.

      e) Any litigation relating to this Agreement shall be brought in the state
or federal courts in the State of New York and each party consents to personal
jurisdiction in such courts.

      f) In the event of litigation relating to this Agreement, the prevailing
party shall be entitled to reimbursement from the other party of its reasonable
attorneys' fees and costs.

      g) This Agreement constitutes the entire agreement of the parties with
respect to the subject matter hereof and supersedes all prior and
contemporaneous oral and written agreements and discussions, and may not be
amended, waived, discharged or terminated except by a written instrument signed
by all the parties hereto.

                                       4
<PAGE>

      h) This Agreement may be executed in as many counterparts as may be
required, and it shall not be necessary that the signature of each party, or
that the signatures of all persons required to bind any party, appear on each
counterpart. It shall be sufficient that the signature of each party, or that
the signatures of the persons required to bind any party, appear on one or more
of such counterparts. All counterparts shall collectively constitute a single
agreement.

      IN WITNESS WHEREOF, the parties have caused this Agreement to be executed
under seal by their respective duly authorized officers as of the date first set
forth above.

----------------------
Jeffrey R. Johnson
President and Chief Executive Officer
Franklin Credit Management Corporation

----------------------
David P. Kalm
Chief Executive Officer
RMTS, LLC

----------------------
Thomas J. Axon
President
James Thomas Realty, LLC

                                       5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00085-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00085-of-00352.parquet"}]]